On November 24, 2023, Moshe Arkin announced that on November 14, 2023, he has sent a letter to Eiger BioPharmaceuticals, Inc and expressed that first, the Company should file a new drug application for Lonafarnib and finance its development through a private offering with the Company?s major shareholders, potentially including Moshe Arkin and/or Propel Bio. Second, and just as importantly, following the offering the Company should place one or more representatives from its major shareholders on the Company?s board of directors. In addition, Moshe Arkin expressed that placing a reputable investor representative on the Board will successfully signal the significant potential of Lonafarnib to the market and have a materially positive impact on the Company?s stock price.

Further, Moshe Arkin stated that he does not believe that allocating resources to the development of Lonafarnib will come at the expense of Avexitide